The global market for idiopathic pulmonary fibrosis expected to reach $8.8 billion by 2027, growing at CAGR 7.3% over the forecast period, driven by increasing drug prices and rapid approval of new treatments.
According to pulmonary fibrosis foundation, the non-pharmacologic management of pulmonary fibrosis (PF) to manage symptoms and prevent future complications includes home pulse oximetry, pulmonary rehabilitation, vaccination, weight management, and lung transplantation. In the United States; in 2013, PF accounted for nearly half of all lung transplants performed.
- Idiopathic pulmonary fibrosis (IPF) is a rare, but serious lung disease. According to the National Institutes of Health, about 100,000 people in the United States have IPF, and approximately 30,000 to 40,000 new cases are found each year.
- Worldwide, IPF affects 13 to 20 out of every 100,000 people. Common comorbid medical conditions found in patients with idiopathic pulmonary fibrosis include chronic obstructive pulmonary disease, obstructive sleep apnea, gastroesophageal reflux disease, and coronary artery disease.
Several different medications have been used for the treatment of PF. Corticosteroids (prednisone), Cyclophosphamide (Cytoxan), Azathioprine (Imuran), Mycophenolate mofetil (Cellcept, Myfortic), N-acetylcysteine (NAC), Nintedanib (Ofev), Pirfenidone (Esbriet, Pirfenex, Pirespa), and Proton pump inhibitors (Prilsec OTC, Nexium, others).
- Some of the therapeutic approaches currently being studied include anti-fibrotic therapies, inhibitors of “growth factor” proteins, stem cell therapies, and genetic research.
- In 2014, US-FDA approved two anti-fibrotic medications are drugs that inhibit or reduce fibrosis in the lung: Ofev (nintedanib) and Esbriet (pirfenidone) for the treatment of patients with IPF.
The global IDF treatment market research report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).
The global idiopathic pulmonary fibrosis (IPF) treatment market segmented by treatment [pharmacological treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), generic Pirfenidone); non-pharmacological treatment (oxygen therapy, pulmonary rehabilitation, mechanical ventilation, lung transplantation, other non-pharmacological treatment)]; patients by disease severity (mild, moderate, severe); and pipeline analysis (Pamrevlumab (FG-3019), GLPG1690, TD139, RVT-1601 (inhaled formulation of, cromolyn sodium), GLPG1205, CC-90001, Setanaxib (GKT831), ND-L02-s0201, PRM-151, KD025, PBI-4050 (3-pentylbenzenacetic, acid sodium salt), NP-120 (ifenprodil), and PLN-74809).
- Both Esbriet and Ofev will continue to draw patient share from other treatments. It is estimated that Esbriet will remain the highest-selling brand in IPF until generic competitors enter the market in 2021, eroding the drug’s sales and allowing Ofev to become the market leader.
- As the first two therapies clinically proven to significantly slow disease progression in IPF patients, both Esbriet (Roche/Shionogi) and Ofev (Boehringer Ingelheim) will enjoy notable uptake in all markets.
- In addition to patients receiving off-label pharmacological therapies, patients previously treated with non-pharmacological treatments will also continue to switch to treatment with Esbriet or Ofev.
- There is currently no therapeutically equivalent or generic version of Esbriet available in the United States and Europe. However, Cipla Limited, world’s leading generic pharmaceutical companies has introduced Pirfenidone in India under the brand name Pirfenex for the treatment of IPF.
- The pathophysiological understanding, clinical diagnostics and therapy of idiopathic pulmonary fibrosis have significantly evolved in recent years. While the introduction of the two antifibrotic drugs pirfenidone and nintedanib led to a significant reduction in lung function decline, there is still no cure for IPF thus, new therapeutic approaches are needed. Currently, several clinical phase II and III trials are focusing on novel therapeutic targets.
- The most prevalent disease severity is moderate IPF, making up a mean of 42% of patients across the US, Japan, and five major EU markets (Germany, France, Italy, and Spain). The next most common severity is mild IPF, at a mean of 32%, while severe IPF constitutes the remaining 26% of patients.
The global IPF market research report is divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
- The vast majority of this growth can be attributed to the US market, which has grown rapidly since the simultaneous approvals of the first two drugs [Ofev (nintedanib) and Esbriet (pirfenidone)] indicated for IPF in 2014.
- The US IPF market is estimated to make up more than 85% of sales in the forecast period. The high prevalence of IPF combined with inflating drug prices will drive sales in the US. On the other hand, lower prevalence and lower costs of treatment will restrict sales in Japan and the five major EU markets.
- Increasing drug prices and market penetration will allow sales in the US to more than triple during the forecast period, while other markets will remain relatively stable.
The global market for idiopathic pulmonary fibrosis research report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global idiopathic pulmonary fibrosis market and profiled in this report include Biogen, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, FibroGen, Inc., Galapagos NV, Liminal BioSciences, Inc. (ProMetic Life Sciences, Inc.), MediciNova, Inc., Merck & Co., Inc. (Afferent Pharmaceuticals, Inc.), Novartis AG, and Roche Holding AG (Promedior, Inc./F. Hoffmann-La Roche).
- Pharmacological Treatment – Drug (Brand)
- Pirfenidone (Esbriet)
- Nintedanib (Ofev)
- Generic Pirfenidone
- Non-pharmacological Treatment
- Oxygen Therapy
- Pulmonary Rehabilitation
- Mechanical Ventilation
- Lung Transplantation
- Other Non-Pharmacological Treatment
- Pharmacological Treatment – Drug (Brand)
- Patients (Disease Severity)
- Pipeline Analysis (Phase III and II)
- Pamrevlumab (FG-3019)
- RVT-1601 (inhaled formulation of cromolyn sodium)
- Setanaxib (GKT831)
- PBI-4050 (3-pentylbenzenacetic acid sodium salt)
- NP-120 (ifenprodil)
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- FibroGen, Inc.
- Galapagos NV
- Liminal BioSciences, Inc. (ProMetic Life Sciences, Inc.)
- MediciNova, Inc.
- Merck & Co., Inc. (Afferent Pharmaceuticals, Inc.)
- Novartis AG
- Roche Holding AG (Promedior, Inc./F. Hoffmann-La Roche)
To request Table of Contents and Sample Pages of this report visit: